ConCallIQ
Go Pro
JAGSONPALPHARMACEUTICALS Healthcare 30 Apr 2026

Jagsonpal Pharmaceuticals Ltd — Q4 FY26

Jagsonpal Pharmaceuticals reported a strong Q4 FY26 recovery with revenue of ₹64 crore (+10% YoY) and PAT of ₹9 crore (+31% YoY), driven by improved MR productivity and sharper...

bullish high
Compare with...
Revenue ₹64 Cr +10%
EBITDA ₹11 Cr +9%
PAT ₹9 Cr +31%
EBITDA Margin 16%
Duration 54 min
Read Time 1 min read

Financial stats pending filing verification

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Cost pressure from Middle East disruptions

Packaging material costs are rising due to Middle East tensions, and CMO partners may pass on cost increases, though management expects limited profitability impact.

medium · analyst_question
R

Execution risk in new product launches

Management acknowledged that new product establishment takes over a year for prescription pickup, and some products may not achieve expected market traction.

medium · management_commentary
R

Concentration risk in top 10 brands

Top 10 brands constitute 58-60% of sales; any slowdown in these brands could materially impact overall growth, though management sees balanced portfolio.

low · data_observation